全部文献期刊会议图书|学者科研项目
中外文文献  中文文献  外文文献
作者:Martina Kluth , Ronald Simon ...
来源:[J].BMC Cancer(IF 3.333), 2017, Vol.17 (1)Springer
摘要:Animal model experiments have suggested a role of the DNA repair protein ERCC1 (Excision Repair Cross-Complementation Group 1) in prostate cancer progression.
作者:Martina Kluth , Claudia Hube-Magg ...
来源:[J].BMC Cancer(IF 3.333), 2015, Vol.15 (1)Springer
摘要:Abstract(#br) Background(#br)Posttranscriptional protein modification by SUMOylation plays an important role in tumor development and progression. In the current study we analyzed prevalence and prognostic impact of the de-SUMOylation enzyme SENP1 in prostate cancer.(#br) Methods...
作者:Martina Kluth , Corinna Wittmer ...
来源:[J].BMC Cancer(IF 3.333), 2016, Vol.16 (1)Springer
摘要:Abstract(#br) Background(#br)TMPRSS2:ERG fusions are frequent in prostate cancer, and occur predominantly in young patients. Several studies had proposed intratumoral heterogeneity of these fusions. This study was designed to determine frequency and extent of ERG fusion hete...
作者:Martina Kluth , Christian Bernreuther ...
来源:[J].BMC Cancer(IF 3.333), 2018, Vol.18 (1), pp.1-9DOAJ
摘要:Abstract Background Prostate Stem Cell Antigen (PSCA) is frequently expressed in prostate cancer but its exact function is unclear. Methods To clarify contradictory findings on the prognostic role of PSCA expression, a tissue microarray containing 13,665 prostate cancers was anal...
作者:Martina Kluth , Claudia Hube-Magg ...
来源:[J].International Journal of Molecular Sciences(IF 2.464), 2015, Vol.16 (4), pp.8591-8606DOAJ
摘要:The VEGFR-1 is suggested to promote tumor progression. In the current study we analyzed prevalence and prognostic impact of the VEGFR-1 by immunohistochemistry on a tissue microarray containing more than 3000 prostate cancer specimens. Results were compared to tumor phenotype, ET...
作者:Martina Kluth , Ronald Simon ...
来源:[J].Scientific Reports(IF 2.927), 2018, Vol.8 (1), pp.1-11DOAJ
摘要:Abstract Here we describe the establishment and characterization of an AR+, PSMA+, ERG+, PTEN−/−, CHD1+/− patient-derived xenograft (PDX model termed ‘C5’, which has been developed from a 60 years old patient suffering from castration-resistant prostate cancer (CRP...

我们正在为您处理中,这可能需要一些时间,请稍等。

资源合作:cnki.scholar@cnki.net, +86-10-82896619   意见反馈:scholar@cnki.net

×